UK markets open in 6 hours 5 minutes

Celldex Therapeutics, Inc. (CLDX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
37.72-0.78 (-2.03%)
At close: 04:00PM EST
38.20 +0.48 (+1.27%)
After hours: 08:00PM EST

Celldex Therapeutics, Inc.

Perryville III Building
Suite 220 53 Frontage Road
Hampton, NJ 08827
United States
908 200 7500

Full-time employees148

Key executives

NameTitlePayExercisedYear born
Mr. Anthony S. Marucci M.B.A.Founder, President, CEO & Director1.14M3.91M1962
Dr. Tibor KelerFounder, Chief Scientific Officer & Executive VP739.03k575.74k1959
Mr. Sam MartinSenior VP, CFO, Secretary & Treasurer617.26k634.9k1971
Dr. Margo Heath-Chiozzi M.D.Senior Vice President of Regulatory Affairs614.12kN/A1957
Dr. Diane C. Young M.D.Senior VP & Chief Medical Officer643.5k2.04M1957
Prof. Joseph P. Schlessinger Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1945
Ms. Sarah CavanaughSenior Vice President of Corporate Affairs & AdministrationN/AN/A1975
Patrick TillSenior Director of Investor Relations & Corporate CommunicationsN/AN/AN/A
Mr. Freddy A. Jimenez Esq.Senior VP & General Counsel579.7kN/A1969
Dr. Ronald A. PepinChief Business Officer & Senior VP441.84kN/A1956
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Corporate governance

Celldex Therapeutics, Inc.’s ISS governance QualityScore as of 1 February 2024 is 1. The pillar scores are Audit: 2; Board: 2; Shareholder rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.